75 results about "Intragastric administration" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of corynebacterium casei in preparation of medicine for preventing and treating lung injury. By constructing a radon inhalation-induced lung injury mouse model, after exposure at different radon levels, the weight of a mouse is reduced, the lung coefficient is increased, the tidal volume of the lung, the ventilation volume per minute and the maximum inspiration flow are reduced, the respiratory function is inhibited, the alveolar cavity of the mouse is abnormally expanded, the pulmonary septum is thickened and fractured, and more fibrin exudation is accompanied; the traditional Chinese medicine composition can be used for effectively inhibiting pulmonary fibrosis and lung injury due to obvious inflammatory infiltration beside bronchial tubes, extravasated blood in small blood vessels and lung tissue collagen deposition, and can be used for gavage of corynebacterium casei to effectively inhibit the above phenomena. Therefore, the corynebacterium casei can be used for preventing and treating lung injury, especially lung injury caused by radon exposure.

The invention relates to a method for constructing a male non-human animal nicotine exposure model, which comprises the following steps: dissolving and extracting contents in a nicotine bag to obtain a nicotine bag content extracting solution; and selecting a male non-human animal, and performing intragastric administration with the nicotine bag content extracting solution to construct the male non-human animal nicotine exposure model. The invention also relates to a nicotine pocket reproductive development safety evaluation method based on the male non-human animal. The method comprises the following steps: taking the male non-human animal nicotine exposure model as a male parent to mate with a normal female non-human animal to generate a filial generation; detecting a parent reproduction index and a filial generation development index; and performing nicotine pocket reproductive development safety evaluation according to the male parent reproductive index and the offspring development index. The nicotine bag reproductive development safety evaluation comprises comparison with a nicotine bag safety standard substance.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention discloses a preeclampsia mouse model. The preeclampsia mouse model is constructed by the following method: (1) combining a female mouse with a male mouse; (2) in the middle stage of pregnancy, intragastric administration of hypoxanthine and oteracil potassium salt is carried out on the pregnant mouse for a period of time; the invention also discloses a construction method and application of the gene. The invention provides a novel preeclampsia modeling mode, hypoxanthine and oteracil potassium salt are combined for use, and the administration dosage and the administration mode of hypoxanthine and oteracil potassium salt are controlled, so that the serum uric acid level of a model mouse is stably increased, preeclampsia change occurs in the model mouse, and the model mouse can be used for treating preeclampsia. The stability, specificity and pathophysiology characteristics of the model are ensured to be similar to those of human preeclampsia, so that the uric acid-induced preeclampsia mouse model is successfully constructed. The uric acid induced preeclampsia mouse model provides a valuable tool for researching the pathogenesis of preeclampsia, evaluating a new treatment method and understanding the effect of serum hyperuricemia in preeclampsia.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention relates to genetic engineering combined lactobacillus salivarius and application of the genetic engineering combined lactobacillus salivarius. The strain is classified and named as combined lactobacillus salivarius CTMT2, and the preservation number of the strain is CCTCC (China Center for Type Culture Collection) M 2025547. After an NIAAA model is injected into the stomach of an alcoholic liver mouse, the acetaldehyde level of the liver of the mouse is obviously reduced, and the alcoholic fatty liver symptom of the mouse is obviously relieved; after long-term intragastric administration of a high-glucose and high-fat modeling mouse, the acetaldehyde level in excrement of the mouse can be obviously reduced, the progress of liver fibrosis is improved, and good application prospects are achieved.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

The invention belongs to the technical field of animal model construction, and particularly provides a construction method and application of a mouse non-alcoholic fatty liver model, and the construction method comprises the following steps: S1, selecting an experimental mouse; s2, a high nitrogen compound aqueous solution with the mass concentration of 4-10 mg / mL is prepared; s3, according to the dosage, the dosage and the administration time, the prepared high-nitrogen compound aqueous solution is fed through the intragastric administration, and the non-alcoholic fatty liver animal model is obtained, the problems that an existing non-alcoholic fatty liver animal model is long in modeling time and expensive in modeling are solved, and the non-alcoholic fatty liver animal model does not need to be fed with high-fat feed, and is simple, convenient and feasible, low in cost, good in repeatability and stable; the establishment period of the non-alcoholic fatty liver animal model can be effectively shortened, the time cost of the medical research of the NAFLD is greatly saved, and a good animal model is provided for researching the pathogenesis and treatment strategy of the NAFLD.

The invention discloses a tree shrew Parkinson's disease model making method which comprises the following specific steps: (1) Macrozam preparation: weighing required Macrozam under a sterile condition, and dissolving the Macrozam in sterilized ultrapure water to prepare a Macrozam working solution with the concentration of 10 mg / mL; (2) gavage: gavage is conducted on the tree shrew with Macrozamine using liquid, the dosage is 40-80 mg / kg according to the mass of the tree shrew body, and a stable tree shrew Parkinson's disease model is established after normal feeding is conducted for two weeks. According to the method, the tree shrew is subjected to intragastric administration with Macrozamine, the dosage is 40-80 mg / kg, and a stable tree shrew Parkinson's disease model can be established after two weeks. According to the scheme, three transformation medical bottlenecks of a traditional model are overcome for the first time through tree shrew nigra-striatum pathway anatomy conservative property, oral transformation advantage and dosage precise control three-dimensional innovation: (1) whole course simulation; (2) channel-level fidelity; and (3) high-value prediction. The model provides an irreplaceable standardized platform for Parkinson's disease mechanism research and clinical transformation.

The invention discloses a preparation method of a gastrointestinal flatulence mouse model, which comprises the following steps: firstly, uniformly mixing a double contrast aerogenesis agent with a solvent to prepare a suspension, and performing mouse intragastric administration to give the suspension to prepare the gastrointestinal flatulence model; and after the modeling succeeds, performing double-index defoaming effect evaluation on the mouse intragastric defoaming agent by adopting the hiccup frequency of the mouse and the volume of gas in the stomach of the mouse. The invention provides a novel modeling method, clinical gastrointestinal flatulence is simulated through chemical induction and oil retention, a basic technology commonly used in a laboratory is adopted, operation is simple and easy to implement, double-index evaluation is adopted, operation or other invasive operation is not needed, animal pain and ethical dispute are remarkably reduced, and the method is suitable for large-scale popularization and application. The method directly promotes the research and development process of the defoaming agent.

The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.

The present application provides a probiotic compound preparation, which is prepared by directly mixing a probiotic compound colony dry powder with inorganic material, wherein the inorganic material is inorganic mineral material subjected to dispersion treatment; and provides a preparation method and application thereof.The probiotic compound preparation provided by the present application can play a role through simple methods such as oral administration and intragastric administration.The inorganic mineral material subjected to dispersion treatment can effectively improve its carrying capacity and colonization capacity, and can also change the microenvironment in the host body through the inorganic mineral material itself, so as to achieve the purpose of changing the composition and quantity of intestinal microflora, and then through the change of the composition and quantity of intestinal microflora, the purpose of preventing, relieving and treating various diseases caused by intestinal flora imbalance can be achieved.

The invention discloses an application of isolithocholic acid in preparation of a medicine for preventing or treating colorectal cancer induced by high fat diet. The invention proves that the isolithocholic acid can be accurately replenished by intragastric administration of 100g / kg of isoLCA at one time, and meanwhile, the isolithocholic acid can obviously inhibit the occurrence of obesity-related colon tumors, reduce the proliferation index of tumor cells and repair the intestinal barrier structure. Isolithocholic acid is endogenous secondary bile acid, can be chemically synthesized or semi-synthesized, is high in safety and good in patient compliance through oral administration, is expected to reduce the occurrence rate of colorectal cancer of obese people, and has important significance in treatment of colorectal cancer.

Use of naphthoquine phosphate in preparation of a medicament for treating autoimmune diseases. It is proved in a mouse rheumatoid arthritis model that the intragastric administration of naphthoquine phosphate can remarkably ameliorate symptoms such as joint redness, swelling, and deformities and reduce the levels of antigen-specific antibodies. It is proved in a mouse systemic lupus erythematosus model that the intragastric administration of naphthoquine phosphate can remarkably reduce the levels of anti-double-stranded DNA antibodies and anti-nuclear antibodies. Pharmacodynamic and pharmacological studies prove that naphthoquine phosphate has ideal immunosuppressive activity and can be used to prepare the medicament for treating autoimmune diseases. Further provided is a pharmaceutical use of naphthoquine phosphate in the treatment and auxiliary treatment of rheumatoid arthritis or systemic lupus erythematosus. The medicament is a pharmaceutical composition consisting of a therapeutically effective amount of naphthoquine phosphate serving as an active ingredient and pharmaceutical excipients.

The invention discloses a method for constructing a coolah source elderly mouse model by using a coprophilous fungus transplantation technology, and belongs to the technical field of biomedicine. According to the method, C57BL / 6N mice are selected and normally fed in groups; the method comprises the following steps: freely drinking antibiotics to construct a sterile environment, and constructing a coolah source old-age mouse model by utilizing a coprophilous fungus transplantation technology; during the test, apparent states such as diet, activity, mental state and defecation of the mouse are observed, and after the test is finished, the expression quantity of senescence factors of each tissue of the mouse is detected by a qPCR (quantitative polymerase chain reaction) method. Test results show that the expression quantity of aging factors of mice can be increased successfully after 6-week intragastric administration of the colacobacterium colati suspension, and it is proved that the mice have aging characterization. The model has obvious advantages and wide application prospects in the aspects of clarification of the aging pathogenesis of the organism and drug research and development, can deeply study drug use of colaz, ensures that colaz is properly treated and potential side effects are minimized, and better improves the safety of drug use.

The invention discloses a construction method of a mixed type rat xerophthalmia animal model. The xerophthalmia animal model is obtained by intragastric administration of flutamide and eye drop of benzalkonium chloride. The invention aims to establish a mixed xerophthalmia animal model through a combined modeling mode of combining flutamide intragastric administration with benzalkonium chloride solution eye dropping, and provides a new idea and possibility for researching the pathogenesis of xerophthalmia and finding a new treatment method and medicine to prevent or delay the course of xerophthalmia.

The present invention provides a use of naphthoquine phosphate in the manufacture of a medicament for the treatment of autoimmune diseases. In a mouse rheumatoid arthritis model, intragastric administration of naphthoquine phosphate has been shown to significantly improve symptoms such as joint redness, swelling, and deformity, and to reduce antigen-specific antibody levels. In a mouse systemic lupus erythematosus model, intragastric administration of naphthoquine has been shown to significantly reduce anti-double-stranded DNA antibody and antinuclear antibody levels. Pharmacological studies have demonstrated that naphthoquine phosphate has excellent immunosuppressive activity and can be used in the manufacture of a medicament for the treatment of autoimmune diseases. The present invention also provides a use of naphthoquine phosphate as a medicament for the treatment and adjunctive treatment of rheumatoid arthritis and systemic lupus erythematosus. The medicament is a pharmaceutical composition containing a therapeutically effective amount of naphthoquine phosphate as an active ingredient and pharmaceutical excipients.

The invention discloses application of resveratrol in preparation of a product for preventing and / or treating unexplained recurrent abortion, and belongs to the technical field of biological medicine. A small dose of resveratrol is subjected to intragastric administration treatment on a mouse with unknown recurrent abortion, so that the resveratrol not only reduces the embryo absorption rate, but also improves the inflammatory response of the decidua tissue of the mouse, improves the Sirt1 level of the decidua tissue of the mouse, and prevents the generation and development of the sterile inflammation of the maternal-fetal interface of the mouse with unknown recurrent abortion; further, the pregnancy rate of the mice with unexplained recurrent abortion is effectively protected and treated. The invention provides a new way and method for treating recurrent abortion caused by unknown reasons.

The invention relates to the technical field of health-care food, and discloses a food composition for improving sperm concentration and a preparation method thereof, the food composition for improving sperm concentration comprises hippocampus, fresh oysters, mulberries, Chinese chive seeds, Chinese wolfberry fruits, algae and nereis. The natural food is used as the raw material, and the spirulina and the nereis are especially added, and the two components have relatively strong antioxidant ability, can effectively remove free radicals in the mouse body, reduce testis injury of the mouse, and further improve the sperm concentration of the mouse. Through intragastric administration of the food composition in the treatment period, it is found that the sperm concentration of a modeling mouse is increased by 2.9 times compared with that of a modeling mouse subjected to intragastric administration with normal saline, and the sperm concentration increasing effect is far higher than that of spermatogenic capsules widely sold in the market. Besides, the food composition is simple in preparation process, the adopted raw materials are all from natural food, and the food composition has the advantages of small toxic and side effects, wide and lasting effect and the like, and is widely distributed in nature, rich in resources and low in production cost.

The present invention belongs to the technical field of biomedicine, and specifically relates to the application of 9-hydroxy pentadecanoic acid in the preparation of a drug for preventing and treating lung injury. By establishing a mouse model of radon inhalation-induced lung injury, the present invention found that after exposure to different radon levels, the body weight of the mice decreased, the lung coefficient increased, the tidal volume, minute ventilation volume and maximum inspiratory flow of the lungs decreased, the respiratory function was inhibited, the alveolar cavities of the mice were abnormally dilated, the lung septum was thickened and fractured, accompanied by more fibrin exudation, obvious inflammatory infiltration appeared beside the bronchi, congestion occurred in the small blood vessels, and collagen deposition occurred in the lung tissue, which could lead to the occurrence of pulmonary fibrosis and cause lung injury. By intragastric administration of 9-hydroxy pentadecanoic acid, the above phenomena can be effectively inhibited. Therefore, 9-hydroxy pentadecanoic acid can be used for the prevention and treatment of lung injury, especially for the prevention and treatment of lung injury caused by radon exposure.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

The invention relates to application of a horseradish tree leaf extract in preparation of fat-reducing medicines or functional foods, and belongs to the technical field of medicines. The application comprises the following steps that S1, mice are evenly divided into five groups according to the weight of the mice after being fed for one week under the conditions of constant temperature and humidity, each group comprises eight mice, and the five groups comprise a normal control Con group, a high-fat and high-cholesterol HFC model group, a low-dose moringa oleifera leaf extract L-MOL intervention group, a high-dose moringa oleifera leaf extract H-MOL intervention group and a positive drug rosiglitazone RSG intervention group; s2, except the normal control Con group, high-fat feed is administered to other groups, administration is performed in an intragastric administration mode at ten o'clock in the morning every day, the weight of the mice is observed and recorded, and continuous administration is performed for 60 days; s3, stopping taking medicine for 24 hours after the step S2, anesthetizing and sampling blood, dissecting after cervical vertebra dislocation and killing, dissecting the abdomen of the mouse, taking a picture, and recording the subcutaneous fat weight and the white fat weight of the abdomen of each group of mouse. The moringa oleifera leaf extract provided by the invention shows an excellent fat reducing effect.

The invention discloses a compound for treating osteosarcoma as well as a preparation method and application thereof. The invention belongs to the technical field of biological medicine. The compound is a 13-methyl-palmatine derivative, and has a structure as shown in the following formula. Experiments prove that the compound 13-methyl-palmatine derivative disclosed by the invention can inhibit proliferation, cloning, migration and invasion capabilities of osteosarcoma cells in vitro. An NYG mouse subcutaneous tumor-bearing experiment proves that the traditional Chinese medicine composition can obviously inhibit the growth of osteosarcoma in vivo. Compared with a positive drug (methotrexate intraperitoneal injection), the 13-methyl-palmatine derivative has a more convenient administration mode (intragastric administration), a safer administration dosage and smaller organ and biochemical index damage degree. The invention provides a new technical means for the treatment of osteosarcoma.

The invention relates to the field of biomedicine, in particular to a mouse hepatic capillary nematode infection model and a construction method and application thereof, and the construction method of the model comprises the following steps: separating and collecting hepatic capillary nematode eggs from naturally infected mouse livers through an artificial digestion method; placing the obtained hepatic capillary nematode eggs in a filter paper culture system containing 1% formaldehyde, and culturing the eggs at a constant temperature of 30 DEG C until the eggs in an infection period; the eggs in the infection period are inoculated into experimental animal bodies through an intragastric administration way, and the inoculation dosage is 500-1500 eggs per animal. The model provided by the invention can be used for researching the pathogenesis of hepatic capillary nematode and evaluating the curative effects of anti-parasitic drugs and immunomodulators, and has important scientific research and clinical application values. And the model has the advantages of simplicity and convenience in operation, good repeatability, reliable experimental result and the like, and provides an important experimental tool for researching the pathological mechanism of hepatic capillary nematode infection.

The invention discloses an application of a compound turtle shell liver-softening tablet in preparing a medicine for treating alveolar echinococcosis, after intervention of the compound turtle shell liver-softening tablet, the focus volume of an alveolar echinococcosis mouse model is reduced, the invasion ability of liver macrophages is reduced, the hepatic fibrosis degree is obviously reduced, and the action mechanism relates to activation of an STING-TBK1 signal channel, so that the liver-softening effect of the compound turtle shell liver-softening tablet is improved. The polarization of the macrophage M1 is induced, so that the fibrosis process is reversed. The dosage forms of the medicine comprise tablets, granules, capsules and oral liquid, and preferably 1g / kg of the medicine is taken for intragastric administration. The invention provides an innovative treatment strategy for the alveolar echinococcosis and the hepatic fibrosis caused by the alveolar echinococcosis, and has a clear molecular mechanism and a remarkable clinical transformation value.

The invention discloses a group of immunogenic peptides with an anti-tumor immune response activating function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequences of the immunogenic peptide are SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and the immunogenic peptide is obtained by the following steps: extracting an enterovirus-like particle (VLPs) preparation from excrement of a healthy mouse, giving the preparation to a tumor model mouse through intragastric administration, and separating and screening from ileum tissues of the mouse by using a liquid chromatography-mass spectrometry technology. The VLPs can be migrated to tumor tissues and presented as the immunogenic peptide through tumor cell MHC-I molecules, so that CD8 + T cells are efficiently activated, a tumor immune microenvironment is remodeled, and tumor growth is inhibited. Experiments show that the immunogenic peptide shows a remarkable anti-tumor effect when being used alone or combined with a PD-1 inhibitor, and the tumor inhibition rate of drug combination can reach 89.4% and is remarkably superior to that of single treatment.

The present application belongs to the technical field of animal model construction, and relates to a insomnia animal model construction method and application with the characteristics of body deficiency, fever and emotional irritability. The application of uncoupling agent as a modeling agent in the construction of insomnia animal model with the characteristics of body deficiency, fever and emotional irritability; the uncoupling agent is carbonic acid cyanide-4-trifluoromethoxy benzyl hydrazone, carbonyl cyanide m-chlorophenyl hydrazone or benzalazoline. The present application uses mice as model animals, uses uncoupling agent as a modeling agent, and suspends or dissolves the modeling agent, then gives the mice intragastric administration once a day, and lasts for 1-4 weeks, to construct a "deficiency and irritability insomnia" insomnia animal model with the characteristics of body deficiency, fever and emotional irritability. The present application has a high degree of consistency with the traditional Chinese medicine theory, and can be well used for the screening and evaluation of anti-insomnia chemical drugs, anti-insomnia traditional Chinese medicine compounds and anti-insomnia health care products.

The invention relates to the field of medicines, and particularly discloses application of bile acid in preparation of a medicine for treating osteoporosis. Research finds that the content of hyodeoxycholic acid (HDCA) in an old individual is remarkably reduced, and the bone mineral density and the bone microstructure can be improved by supplementing the HDCA. Animal experiment results show that the HDCA can significantly inhibit bone mass loss and improve bone quality through oral administration and intragastric administration, and the effect of the HDCA depends on a bile acid receptor TGR5. HDCA is provided as an active component for treating osteoporosis for the first time, and a new drug candidate and an action mechanism can be provided for prevention and treatment of osteoporosis.

The present invention provides methods for increasing the systemic bioavailability of a polypeptide therapeutic administered orally, via oral gavage, via nasogastric gavage, or intragastric administration, comprising administering the polypeptide therapeutic to the stomach of a human or non-human animal as part of one or more dosage forms together with an alginate oligomer and, optionally, a gastrointestinal permeation enhancer, wherein the one or more dosage forms do not, in addition to the polypeptide therapeutic, the alginate oligomer, and, if used, the gastrointestinal permeation enhancer, have a coating that provides substantial protection from the gastric environment. Such methods allow for the systemic treatment or prevention of diseases, conditions, or complications thereof that are responsive to or prevented by the polypeptide therapeutic via oral, oral gavage, via nasogastric gavage, or intragastric administration. Further provided are compositions comprising an alginate oligomer, a polypeptide therapeutic, and, optionally, a gastrointestinal permeation enhancer for use in such methods.

The invention belongs to the field of medicine and health, and particularly relates to application of fresh traditional Chinese medicine radix puerariae exosome-shaped vesicles P-ELNs in medicine or health food for preventing and treating irritable bowel syndrome, the P-ELNs serving as an active ingredient can improve expression of colonic intestinal mucus protein MUC2 and tight junction protein ZO-1 and improve mucous membrane barrier integrity; the inhibition of the expression level of proinflammatory factors (such as TNF-alpha, IL-6, IL-1beta and NF-kappa B) indicates that the action mechanism may involve the synergistic effect of inflammation inhibition and barrier repair. Toxicological experiments show that the P-ELNs have no toxicity after long-term intragastric administration, have no adverse effects on heart, liver, spleen, lung and kidney functions, and have good oral safety and tissue tolerance. The indications comprise anti-inflammatory treatment of active-stage UC patients; maintenance and barrier repair of patients in the UC remission period; the UC disease course is more than or equal to 8 years, and a preventive medicine is applied to high-risk people with cancerization family history and the like; the invention relates to auxiliary treatment of UC-CAC early cancerization patients.